Search Results - "BLAU, Igor"

Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology by Scheibe, Franziska, Ostendorf, Lennard, Prüss, Harald, Radbruch, Helena, Aschman, Tom, Hoffmann, Sarah, Blau, Igor‐Wolfgang, Meisel, Christian, Alexander, Tobias, Meisel, Andreas

“…Background and purpose A fraction of patients with antibody‐mediated autoimmune diseases remain unresponsive to first‐/second‐line and sometimes even to…”
Get full text

Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals by Tranter, Eva, Frentsch, Marco, Hütter‐Krönke, Marie Luise, Vuong, Giang Lam, Busch, David, Loyal, Lucie, Henze, Larissa, Rosnev, Stanislav, Blau, Igor‐Wolfgang, Thiel, Andreas, Beule, Dieter, Bullinger, Lars, Obermayer, Benedikt, Na, Il‐Kang

“…Despite extensive research on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination responses in healthy individuals, there is comparatively…”
Get full text

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients by Weinhold, Niels, Salwender, Hans J, Cairns, David A, Raab, Marc S, Waldron, George, Blau, Igor W, Bertsch, Uta, Hielscher, Thomas, Morgan, Gareth J, Jauch, Anna, Davies, Faith E, Hänel, Mathias, Cook, Gordon, Scheid, Christoph, Houlston, Richard, Goldschmidt, Hartmut, Jackson, Graham, Kaiser, Martin F

Get full text

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT by Schmidt-Hieber, Martin, Labopin, Myriam, Beelen, Dietrich, Volin, Liisa, Ehninger, Gerhard, Finke, Jürgen, Socié, Gerard, Schwerdtfeger, Rainer, Kröger, Nicolaus, Ganser, Arnold, Niederwieser, Dietger, Polge, Emmanuelle, Blau, Igor W., Mohty, Mohamad

“…We analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV) serostatus in 16 628 de novo acute leukemia patients after allogeneic stem cell…”
Get full text

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel by Jiang, Sihe, Penack, Olaf, Terzer, Tobias, Schult, David, Majer-Lauterbach, Joshua, Radujkovic, Aleksandar, Blau, Igor W, Bullinger, Lars, Müller-Tidow, Carsten, Dreger, Peter, Luft, Thomas

“…No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a major complication of allogeneic stem…”
Get full text

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation by Hütter, Gero, Nowak, Daniel, Mossner, Maximilian, Ganepola, Susanne, Müßig, Arne, Allers, Kristina, Schneider, Thomas, Hofmann, Jörg, Hofmann, Wolf K, Kücherer, Claudia, Blau, Olga, Blau, Igor W, Thiel, Eckhard

“…To infect cells, human immunodeficiency virus (HIV) binds the CD4 receptor and a chemokine coreceptor, CCR5 or CXCR4. In an HIV-infected patient with acute…”
Get full text

Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years by Bazarbachi, Ali, Schmid, Christoph, Labopin, Myriam, Beelen, Dietrich, Wolfgang Blau, Igor, Potter, Victoria, Niittyvuopio, Riitta, Socié, Gerard, Blaise, Didier, Sanz, Jaime, Ciceri, Fabio, Abou Dalle, Iman, Spyridonidis, Alexandros, Bug, Gesine, Esteve, Jordi, Savani, Bipin N, Nagler, Arnon, Mohty, Mohamad

“…Relapsed acute myeloid leukemia (AML) post allogeneic hematopoietic cell transplantation (allo-HCT) has a dismal prognosis. To assess prognosis of patients…”
Get full text

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients by Christen, Friederike, Hoyer, Kaja, Yoshida, Kenichi, Hou, Hsin-An, Waldhueter, Nils, Heuser, Michael, Hills, Robert K., Chan, Willy, Hablesreiter, Raphael, Blau, Olga, Ochi, Yotaro, Klement, Piroska, Chou, Wen-Chien, Blau, Igor-Wolfgang, Tang, Jih-Luh, Zemojtel, Tomasz, Shiraishi, Yuichi, Shiozawa, Yusuke, Thol, Felicitas, Ganser, Arnold, Löwenberg, Bob, Linch, David C., Bullinger, Lars, Valk, Peter J.M., Tien, Hwei-Fang, Gale, Rosemary E., Ogawa, Seishi, Damm, Frederik

“…Acute myeloid leukemia with t(8;21)(q22;q22) is characterized by considerable clinical and biological heterogeneity leading to relapse in up to 40% of…”
Get full text

Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse by Garg, Manoj, Nagata, Yasunobu, Kanojia, Deepika, Mayakonda, Anand, Yoshida, Kenichi, Haridas Keloth, Sreya, Zang, Zhi Jiang, Okuno, Yusuke, Shiraishi, Yuichi, Chiba, Kenichi, Tanaka, Hiroko, Miyano, Satoru, Ding, Ling-Wen, Alpermann, Tamara, Sun, Qiao-Yang, Lin, De-Chen, Chien, Wenwen, Madan, Vikas, Liu, Li-Zhen, Tan, Kar-Tong, Sampath, Abhishek, Venkatesan, Subhashree, Inokuchi, Koiti, Wakita, Satoshi, Yamaguchi, Hiroki, Chng, Wee Joo, Kham, Shirley-Kow Yin, Yeoh, Allen Eng-Juh, Sanada, Masashi, Schiller, Joanna, Kreuzer, Karl-Anton, Kornblau, Steven M., Kantarjian, Hagop M., Haferlach, Torsten, Lill, Michael, Kuo, Ming-Chung, Shih, Lee-Yung, Blau, Igor-Wolfgang, Blau, Olga, Yang, Henry, Ogawa, Seishi, Koeffler, H. Phillip

“…Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy with a grave prognosis. To…”
Get full text

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial by SERVE, Hubert, KRUG, Utz, FISCHER, Thomas, GIAGOUNIDIS, Aristoteles, NEUBAUER, Andreas, REICHLE, Albrecht, AULITZKY, Walter, NOPPENEY, Richard, BLAU, Igor, KUNZMANN, Volker, STUHLMANN, Reingard, KRÄMER, Alwin, WAGNER, Ruth, KREUZER, Karl-Anton, BRANDTS, Christian, STEFFEN, Björn, THIEDE, Christian, MÜLLER-TIDOW, Carsten, EHNINGER, Gerhard, BERDEL, Wolfgang E, SAUERLAND, M. Cristina, HEINECKE, Achim, BRUNNBERG, Uta, SCHAICH, Markus, OTTMANN, Oliver, DUYSTER, Justus, WANDT, Hannes

“…The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the…”
Get full text

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p by Neben, Kai, Lokhorst, Henk M., Jauch, Anna, Bertsch, Uta, Hielscher, Thomas, van der Holt, Bronno, Salwender, Hans, Blau, Igor W., Weisel, Katja, Pfreundschuh, Michael, Scheid, Christof, Dührsen, Ulrich, Lindemann, Walter, Schmidt-Wolf, Ingo G.H., Peter, Norma, Teschendorf, Christian, Martin, Hans, Haenel, Mathias, Derigs, Hans G., Raab, Marc S., Ho, Anthony D., van de Velde, Helgi, Hose, Dirk, Sonneveld, Pieter, Goldschmidt, Hartmut

“…In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. In the…”
Get full text

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region by Berenstein, Rimma, Blau, Olga, Nogai, Axel, Waechter, Marlies, Slonova, Ekaterina, Schmidt-Hieber, Martin, Kunitz, Annegret, Pezzutto, Antonio, Doerken, Bernd, Blau, Igor Wolfgang

“…Alterations and senescence in bone marrow mesenchymal stromal cells of multiple myeloma patients (MM-BMMSCs) have become an important research focus. However…”
Get full text

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma by Petrucci, Maria T., Giraldo, Pilar, Corradini, Paolo, Teixeira, Adriana, Dimopoulos, Meletios A., Blau, Igor W., Drach, Johannes, Angermund, Ralf, Allietta, Nathalie, Broer, Esther, Mitchell, Vivien, Bladé, Joan

“…Summary Multiple myeloma (MM) typically follows a relapsing course with many patients requiring multiple therapies. This single‐arm phase 2 study prospectively…”
Get full text

Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation by Gagelmann, Nico, Schuh, Claudia, Flossdorf, Sarah, Kunadt, Desiree, Stelljes, Matthias, Blau, Igor W., Brecht, Arne, Bethge, Wolfgang, Schroeder, Thomas, Wulf, Gerald, Sala, Elisa, Bug, Gesine, Fleischhauer, Katharina, Kröger, Nicolaus

“…One key aspect of allogeneic hematopoietic cell transplantation (HCT) is pretransplant conditioning, balancing risk for relapse versus non‐relapse mortality…”
Get full text

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study by Weller, Jan Frederic, Lengerke, Claudia, Finke, Jürgen, Schetelig, Johannes, Platzbecker, Uwe, Einsele, Hermann, Schroeder, Thomas, Faul, Christoph, Stelljes, Matthias, Dreger, Peter, Blau, Igor W, Wulf, Gerald, Tischer, Johanna, Scheid, Christoph, Elmaagacli, Ahmet, Neidlinger, Helga, Flossdorf, Sarah, Bornhäuser, Martin, Bethge, Wolfgang, Fleischhauer, Katharina, Kröger, Nicolaus, De Wreede, Liesbeth C, Christopeit, Maximilian

“…Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been…”
Get full text

Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database by Scheid, Christof, Blau, Igor W., Sellner, Leopold, Ratsch, Boris A., Basic, Edin

“…Objectives Emerging treatments for relapsed or refractory multiple myeloma (rrMM) have led to increasing options for many patients. This study aimed to assess…”
Get full text

Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts by Blau, Olga, Baldus, Claudia Dorothea, Hofmann, Wolf-Karsten, Thiel, Gundula, Nolte, Florian, Burmeister, Thomas, Türkmen, Seval, Benlasfer, Ouidad, Schümann, Elke, Sindram, Annette, Molkentin, Mara, Mundlos, Stefan, Keilholz, Ulrich, Thiel, Eckhard, Blau, Igor Wolfgang

“…Mesenchymal stromal cells (MSCs) are an essential cell type of the hematopoietic microenvironment. Concerns have been raised about the possibility that MSCs…”
Get full text

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial by Goldschmidt, Hartmut, Mai, Elias K., Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Merz, Maximilian, Munder, Markus, Lindemann, Hans-Walter, Hügle-Dörr, Barbara, Tichy, Diana, Giesen, Nicola, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Rabold, Bernhard, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Salwender, Hans J.

“…The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR)…”
Get full text

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation by Ocio, Enrique M., Perrot, Aurore, Bories, Pierre, San-Miguel, Jesus F., Blau, Igor W., Karlin, Lionel, Martinez-Lopez, Joaquin, Wang, Song-Yau, Bringhen, Sara, Marcatti, Magda, Mateos, María-Victoria, Rodriguez-Otero, Paula, Oliva, Stefania, Nogai, Axel, Le Roux, Nadia, Dong, Liyan, Macé, Sandrine, Gassiot, Matthieu, Fitzmaurice, Thomas, Oprea, Corina, Moreau, Philippe

“…Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from…”
Get full text

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients by Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, Goldschmidt, Hartmut

“…Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction…”
Get full text